GlassScriptPhysician profile
Kioumars Mostafizi
NPI 1477531754
$9,858.10
in general payments reported to CMS, 2019-2025
36 companies · $2,149 in 2025
The $2,149 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,669 · 2020: $591 · 2021: $655 · 2022: $3,013 · 2023: $752 · 2024: $1,029 · 2025: $2,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,529 · Travel and Lodging: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,528.66 |
| Travel and Lodging | $401.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,364.60 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $1,392.42 | 2019-2025 | |
| Abiomed | $1,058.83 | 2019-2025 | Impella |
| Aop Health US, LLC | $804.75 | 2025 | Rapiblyk |
| Cardiovascular Systems INC. | $800.53 | 2019 | |
| Boston Scientific Corporation | $554.62 | 2021-2025 | General - Ep, Watchman Flx, General - Crm_crm |
| Philips North America LLC | $401.96 | 2025 | Coronary Other |
| Janssen Pharmaceuticals, INC | $259.89 | 2019-2024 | Xarelto |
| Edwards Lifesciences Corporation | $242.07 | 2022-2025 | Sapien 3 Ultra Resilia, Pascal |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $240.53 | 2022-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $196.46 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $174.25 | 2021-2025 | Verquvo |
| Cardiac Dimensions, INC. | $155.61 | 2025 | |
| Cvrx, INC. | $119.45 | 2024-2025 | Barostim Neo System |
| Inspire Medical Systems, INC. | $117.16 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $113.17 | 2023 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $112.69 | 2019-2025 | Eliquis |
| Pfizer INC. | $101.83 | 2019-2025 | |
| Shockwave Medical, INC | $93.27 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Actelion Pharmaceuticals US, INC. | $77.09 | 2024-2025 | Opsumit, Uptravi |
| Welch Allyn | $66.07 | 2021 | |
| Kestra Medical Technology Services, INC. | $57.17 | 2024 | Assure Wcd |
| Astrazeneca Pharmaceuticals LP | $51.06 | 2019-2025 | Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.77 | 2020-2023 | Jardiance |
| Medtronic Vascular, INC. | $40.95 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $28.16 | 2022 | |
| Chiesi USA, INC. | $26.27 | 2020-2023 | Cleviprex, Kengreal |
| Novo Nordisk INC | $25.10 | 2025 | Ozempic |
| Bardy Diagnostics, INC. | $25.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $20.00 | 2021 | |
| Esperion Therapeutics, INC. | $18.54 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $17.22 | 2024 | |
| Amgen INC. | $15.15 | 2019 | |
| Itamar Medical INC | $15.00 | 2021 | |
| Janssen Biotech, INC. | $14.01 | 2024 | Opsumit |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kioumars Mostafizi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.